1. Home
  2. MBAI vs BOLT Comparison

MBAI vs BOLT Comparison

Compare MBAI & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.65

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$4.53

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBAI
BOLT
Founded
2004
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
10.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MBAI
BOLT
Price
$1.65
$4.53
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$34.00
AVG Volume (30 Days)
49.9K
16.8K
Earning Date
05-08-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,695,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$56.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.07
52 Week Low
$1.31
$0.26
52 Week High
$3.92
$7.35

Technical Indicators

Market Signals
Indicator
MBAI
BOLT
Relative Strength Index (RSI) 49.18 45.22
Support Level $1.38 $4.42
Resistance Level $1.89 $5.36
Average True Range (ATR) 0.14 0.31
MACD -0.01 0.08
Stochastic Oscillator 30.77 54.73

Price Performance

Historical Comparison
MBAI
BOLT

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Share on Social Networks: